Catalyst Event
Alnylam Pharmaceuticals Inc (ALNY) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
3/24/2026, 12:00:00 AM
During an investor webinar, Alnylam highlighted strong commercial momentum for its drug AMVUTTRA and reiterated its 2026 TTR revenue guidance of $4.4 billion to $4.7 billion. The company also announced strategic collaborations with Viz.ai and the American Heart Association to accelerate patient diagnosis.
Korean Translation
투자자 웨비나에서 심장질환 치료제 AMVUTTRA의 강력한 상업적 모멘텀을 강조하고 2026년 TTR(트랜스티레틴) 관련 매출 가이던스 44억~47억 달러를 재확인함. 또한 환자 진단을 가속화하기 위해 Viz.ai 및 미국심장협회(AHA)와의 전략적 협력을 발표함.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Next earnings release for Q4 fiscal 2026 on June 1, 2026, scheduled.
6/1/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Biogen's Q1 2026 earnings release is expected around this date, based on past reporting schedules. Earnings releases typically result in moderate price volatility.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to report its Q1 2026 earnings on May 7, 2026, with analysts forecasting an EPS of approximately -$0.55. Market impact is estimated at ≥1% as earnings dates are routine; scheduled.
5/7/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q1 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM